PPARγ signaling is required for mediating EETs protective effects in neonatal cardiomyocytes exposed to LPS

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Samokhvalov, Victor ^a   Vriend, Jelle ^a,b   Jamieson, Kristi L ^a   Akhnokh, Maria K ^a   Manne, Rajkumar ^c   Falck, John R ^c   Seubert, John M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cardiac cells; Epoxyeicosatrienoic acid; Inflammation; LPS; PPAR

Indexed keywords

EID: 84949118062     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00242     Document Type: Article

References (57)

1. Akira, S., Takeda, K., and Kaisho, T. (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2, 675-680. doi: 10.1038/90609
2. Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R.,et al. (1999). PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4, 585-595. doi: 10.1016/S1097-2765(00)80209-9
3. Batchu, S. N., Chaudhary, K. R., El-Sikhry, H., Yang, W., Light, P. E., Oudit, G. Y.,et al. (2012). Role of PI3Kalpha and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection. J. Mol. Cell. Cardiol. 53, 43-52. doi: 10.1016/j.yjmcc.2012.04.008
4. Batchu, S. N., Lee, S. B., Qadhi, R. S., Chaudhary, K. R., El-Sikhry, H., Kodela, R.,et al. (2011). Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. Br. J. Pharmacol. 162, 897-907. doi: 10.1111/j.1476-5381.2010.01093.x
5. Ben-Shaul, V., Lomnitski, L., Nyska, A., Zurovsky, Y., Bergman, M., and Grossman, S. (2001). The effect of natural antioxidants, NAO and apocynin, on oxidative stress in the rat heart following LPS challenge. Toxicol. Lett. 123, 1-10. doi: 10.1016/S0378-4274(01)00369-1
6. Bocher, V., Chinetti, G., Fruchart, J. C., and Staels, B. (2002). [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]. J. Soc. Biol. 196, 47-52. doi: 10.1155/S1110724304308065
7. Carlson, D. L., Willis, M. S., White, D. J., Horton, J. W., and Giroir, B. P. (2005). Tumor necrosis factor-alpha-induced caspase activation mediates endotoxin-related cardiac dysfunction. Crit. Care Med. 33, 1021-1028. doi: 10.1097/01.CCM.0000163398.79679.66
8. Charalambous, B. M., Stephens, R. C., Feavers, I. M., and Montgomery, H. E. (2007). Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 28, 15-23. doi: 10.1097/shk.0b013e318033ebc5
9. Chinetti, G., Fruchart, J. C., and Staels, B. (2001). Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z. Kardiol. 90(Suppl. 3), 125-132. doi: 10.1007/s003920170034
10. Choumar, A., Tarhuni, A., Letteron, P., Reyl-Desmars, F., Dauhoo, N., Damasse, J.,et al. (2011). Lipopolysaccharide-induced mitochondrial DNA depletion. Antioxid. Redox. Signal. 15, 2837-2854. doi: 10.1089/ars.2010.3713
11. Chuang, C. C., Yang, R. S., Tsai, K. S., Ho, F. M., and Liu, S. H. (2007). Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor gamma signaling. Endocrinology 148, 4267-4275. doi: 10.1210/en.2007-2179
12. Delerive, P., Fruchart, J. C., and Staels, B. (2001). Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169, 453-459. doi: 10.1677/joe.0.1690453
13. Deng, Y., Theken, K. N., and Lee, C. R. (2010). Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J. Mol. Cell. Cardiol. 48, 331-341. doi: 10.1016/j.yjmcc.2009.10.022
14. Desvergne, B., and Wahli, W. (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688. doi: 10.1210/edrv.20.5.0380
15. Dhanasekaran, A., Gruenloh, S. K., Buonaccorsi, J. N., Zhang, R., Gross, G. J., Falck, J. R.,et al. (2008). Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am. J. Physiol. Heart Circ. Physiol. 294, H724-H735. doi: 10.1152/ajpheart.00979.2007
16. Drosatos, K., Drosatos-Tampakaki, Z., Khan, R., Homma, S., Schulze, P. C., Zannis, V. I.,et al. (2011). Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. J. Biol. Chem. 286, 36331-36339. doi: 10.1074/jbc. M111.272146
17. Fallach, R., Shainberg, A., Avlas, O., Fainblut, M., Chepurko, Y., Porat, E.,et al. (2010). Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J. Mol. Cell. Cardiol. 48, 1236-1244. doi: 10.1016/j.yjmcc.2010.02.020
18. Fang, X., Kaduce, T. L., Weintraub, N. L., Harmon, S., Teesch, L. M., Morisseau, C.,et al. (2001). Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J. Biol. Chem. 276, 14867-14874. doi: 10.1074/jbc. M011761200
19. Feingold, K., Kim, M. S., Shigenaga, J., Moser, A., and Grunfeld, C. (2004). Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am. J. Physiol. Endocrinol. Metab. 286, E201-207. doi: 10.1152/ajpendo.00205.2003
20. Gabay, C., and Kushner, I. (1999). Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448-454. doi: 10.1056/NEJM199902113400607
21. Hambleton, J., Weinstein, S. L., Lem, L., and Defranco, A. L. (1996). Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc. Natl. Acad. Sci. U.S.A. 93, 2774-2778. doi: 10.1073/pnas.93.7.2774
22. Imig, J. D. (2012). Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 92, 101-130. doi: 10.1152/physrev.00021.2011
23. Jones, D. C., Ding, X., and Daynes, R. A. (2002). Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J. Biol. Chem. 277, 6838-6845. doi: 10.1074/jbc. M106908200
24. Katragadda, D., Batchu, S. N., Cho, W. J., Chaudhary, K. R., Falck, J. R., and Seubert, J. M. (2009). Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J. Mol. Cell. Cardiol. 46, 867-875. doi: 10.1016/j.yjmcc.2009.02.028
25. Kim, I. H., Morisseau, C., Watanabe, T., and Hammock, B. D. (2004). Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J. Med. Chem. 47, 2110-2122. doi: 10.1021/jm030514j
26. Kozak, W., Aronoff, D. M., Boutaud, O., and Kozak, A. (2003). 11,12-epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide. Exp. Biol. Med. (Maywood) 228, 786-794.
27. Levick, S. P., Loch, D. C., Taylor, S. M., and Janicki, J. S. (2007). Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J. Immunol. 178, 641-646. doi: 10.4049/jimmunol.178.2.641
28. Liu, Y., Zhang, Y., Schmelzer, K., Lee, T. S., Fang, X., Zhu, Y.,et al. (2005). The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 102, 16747-16752. doi: 10.1073/pnas.0508081102
29. Maitra, U., Chang, S., Singh, N., and Li, L. (2009). Molecular mechanism underlying the suppression of lipid oxidation during endotoxemia. Mol. Immunol. 47, 420-425. doi: 10.1016/j.molimm.2009.08.023
30. Mishra, P., Paramasivam, S. K., Thylur, R. P., Rana, A., and Rana, B. (2010). Peroxisome proliferator-activated receptor gamma ligand-mediated apoptosis of hepatocellular carcinoma cells depends upon modulation of PI3Kinase pathway independent of Akt. J. Mol. Signal. 5, 20. doi: 10.1186/1750-2187-5-20
31. Moraes, L. A., Piqueras, L., and Bishop-Bailey, D. (2006). Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. 110, 371-385. doi: 10.1016/j.pharmthera.2005.08.007.
32. Ng, V. Y., Huang, Y., Reddy, L. M., Falck, J. R., Lin, E. T., and Kroetz, D. L. (2007). Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab. Dispos. 35, 1126-1134. doi: 10.1124/dmd.106.013839
33. Niebauer, J., Volk, H. D., Kemp, M., Dominguez, M., Schumann, R. R., Rauchhaus, M.,et al. (1999). Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353, 1838-1842. doi: 10.1016/S0140-6736(98)09286-9281
34. Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K.,et al. (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279. doi: 10.1126/science.285.5431.1276
35. Oddis, C. V., and Finkel, M. S. (1995). Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem. Biophys. Res. Commun. 213, 1002-1009. doi: 10.1006/bbrc.1995.2228
36. Ohlsson, K., Bjork, P., Bergenfeldt, M., Hageman, R., and Thompson, R. C. (1990). Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348, 550-552. doi: 10.1038/348550a0
37. Opal, S. M., Scannon, P. J., Vincent, J. L., White, M., Carroll, S. F., Palardy, J. E.,et al. (1999). Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J. Infect. Dis. 180, 1584-1589. doi: 10.1086/315093
38. Ridker, P. M., and Silvertown, J. D. (2008). Inflammation, C-reactive protein, and atherothrombosis. J. Periodontol. 79, 1544-1551. doi: 10.1902/jop.2008.080249
39. Roman, R. J. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185. doi: 10.1152/physrev.00021.2001
40. Rompe, F., Artuc, M., Hallberg, A., Alterman, M., Stroder, K., Thone-Reineke, C.,et al. (2010). Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55, 924-931. doi: 10.1161/HYPERTENSIONAHA.109.147843
41. Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G., Moore, K., Milstone, D. S.,et al. (1999). PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4, 611-617. doi: 10.1016/S1097-2765(00)80211-7
42. Rosenthal, M. D., Rzigalinski, B. A., Blackmore, P. F., and Franson, R. C. (1995). Cellular regulation of arachidonate mobilization and metabolism. Prostaglandins Leukot. Essent. Fatty Acids. 52, 93-98. doi: 10.1016/0952-3278(95)90004-7
43. Samokhvalov, V., Alsaleh, N., El-Sikhry, H. E., Jamieson, K. L., Chen, C. B., Lopaschuk, D. G.,et al. (2013). Epoxyeicosatrienoic acids protect cardiac cells during starvation by modulating an autophagic response. Cell Death Dis. 4, e885. doi: 10.1038/cddis.2013.418
44. Samokhvalov, V., Ussher, J. R., Fillmore, N., Armstrong, I. K., Keung, W., Moroz, D.,et al. (2012). Inhibition of malonyl-CoA decarboxylase reduces the inflammatory response associated with insulin resistance. Am. J. Physiol. Endocrinol. Metab. 303, E1459-E1468. doi: 10.1152/ajpendo.00018.2012
45. Seargent, J. M., Yates, E. A., and Gill, J. H. (2004). GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br. J. Pharmacol. 143, 933-937. doi: 10.1038/sj.bjp.0705973
46. Seubert, J. M., Darmon, A. J., El-Kadi, A. O., D'souza, S. J., and Bend, J. R. (2002). Apoptosis in murine hepatoma hepa 1c1c7 wild-type, C12, and C4 cells mediated by bilirubin. Mol. Pharmacol. 62, 257-264. doi: 10.1124/mol.62.2.257
47. Shahabi, P., Siest, G., and Visvikis-Siest, S. (2014). Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids. Drug Metab. Rev. 46, 33-56. doi: 10.3109/03602532.2013.837916
48. Spector, A. A., and Norris, A. W. (2007). Action of epoxyeicosatrienoic acids on cellular function. Am. J. Physiol. Cell. Physiol. 292, C996-C1012. doi: 10.1152/ajpcell.00402.2006
49. Turdi, S., Han, X., Huff, A. F., Roe, N. D., Hu, N., Gao, F.,et al. (2012). Cardiac-specific overexpression of catalase attenuates lipopolysaccharide-induced myocardial contractile dysfunction: role of autophagy. Free Radic. Biol. Med. 53, 1327-1338. doi: 10.1016/j.freeradbiomed.2012.07.084
50. Wang, N., Verna, L., Chen, N. G., Chen, J., Li, H., Forman, B. M.,et al. (2002). Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 277, 34176-34181. doi: 10.1074/jbc. M203436200
51. Wang, P., Henning, S. M., and Heber, D. (2010). Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS ONE 5:e10202. doi: 10.1371/journal.pone.0010202
52. Widstrom, R. L., Norris, A. W., Van Der Veer, J., and Spector, A. A. (2003). Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry 42, 11762-11767. doi: 10.1021/bi034971d
53. Wray, J., and Bishop-Bailey, D. (2008). Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. Exp. Physiol. 93, 148-154. doi: 10.1113/expphysiol.2007.038612
54. Xu, D. Y., Davis, B. B., Wang, Z. H., Zhao, S. P., Wasti, B., Liu, Z. L.,et al. (2013). A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARgamma to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. Int. J. Cardiol. 167, 1298-1304. doi: 10.1016/j.ijcard.2012.03.167
55. Yasuda, S., and Lew, W. Y. (1997). Lipopolysaccharide depresses cardiac contractility and beta-adrenergic contractile response by decreasing myofilament response to Ca2+ in cardiac myocytes. Circ. Res. 81, 1011-1020. doi: 10.1161/01.RES.81.6.1011
56. Zernecke, A., Bernhagen, J., and Weber, C. (2008). Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117, 1594-1602. doi: 10.1161/CIRCULATIONAHA.107.729125
57. Zhao, G., Wang, J., Xu, X., Jing, Y., Tu, L., Li, X.,et al. (2012). Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-alpha-induced injury. J. Lipid Res. 53, 456-466. doi: 10.1194/jlr. M017319